These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18221118)

  • 1. MMP inhibitors in cardiac diseases: an update.
    Dormán G; Kocsis-Szommer K; Spadoni C; Ferdinandy P
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):186-94. PubMed ID: 18221118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
    Peterson JT
    Cardiovasc Res; 2006 Feb; 69(3):677-87. PubMed ID: 16413004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
    Peterson JT
    Heart Fail Rev; 2004 Jan; 9(1):63-79. PubMed ID: 14739769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced hit-to-lead process using bioanalogous lead evolution and chemogenomics: application in designing selective matrix metalloprotease inhibitors.
    Papp A; Szommer T; Barna L; Gyimesi G; Ferdinandy P; Spadoni C; Darvas F; Fujita T; Urge L; Dormán G
    Expert Opin Drug Discov; 2007 May; 2(5):707-23. PubMed ID: 23488960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.
    Fields GB
    Cells; 2019 Aug; 8(9):. PubMed ID: 31461880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2004 Nov; 11(22):2911-77. PubMed ID: 15544483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.
    Sang QX; Jin Y; Newcomer RG; Monroe SC; Fang X; Hurst DR; Lee S; Cao Q; Schwartz MA
    Curr Top Med Chem; 2006; 6(4):289-316. PubMed ID: 16611144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors?
    Corbitt CA; Lin J; Lindsey ML
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):135-42. PubMed ID: 18221058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
    Pirard B
    Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metalloproteinase inhibitors: biological actions and therapeutic opportunities.
    Baker AH; Edwards DR; Murphy G
    J Cell Sci; 2002 Oct; 115(Pt 19):3719-27. PubMed ID: 12235282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
    Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis.
    Leppert D; Lindberg RL; Kappos L; Leib SL
    Brain Res Brain Res Rev; 2001 Oct; 36(2-3):249-57. PubMed ID: 11690622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY; Feldman AM
    Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases are involved in cardiovascular diseases.
    Azevedo A; Prado AF; Antonio RC; Issa JP; Gerlach RF
    Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):301-14. PubMed ID: 24974977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective matrix metalloproteinase inhibitors for cancer.
    Lia NG; Shib ZH; Tang YP; Duan JA
    Curr Med Chem; 2009; 16(29):3805-27. PubMed ID: 19747139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
    Lizotte-Waniewski M; Brew K; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.